Treatment with niraparib and/or lasofoxifene significantly reduced the expression of the proliferative marker Ki67 in tumor xenografts derived from ERα Y537S mutated MCF7 cells (Additional File 8 A). This evidence concerns the gene ESR1 and neoplasm.